42 results about "VEGFR Inhibitor" patented technology

The invention relates to a pharmaceutical composition containing crenolanib and application of the pharmaceutical composition. The present invention relates to the use of a combination comprising crenolanib or a salt thereof and a VEGF / VEGFR inhibitor of non-axitinib for the preparation of a medicament for the treatment of proliferative diseases, wherein the crenolanib and the VEGF / VEGFR inhibitorof non-axitinib are provided for a subject in at least one of a sequential or simultaneous manner for treating proliferative diseases, and the subject is a human subject.

The invention discloses a method for predicting sensitivity to vascular endothelial growth factor receptor inhibitor. The present invention relates to a method for predicting the sensitivity to treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, by using a biomarker. An effective means and anticancer therapy for cancer treatment of liver cancer are selected by predicting the effect of treatment with VEGFR inhibitors on liver cancer patients through the present invention, thereby increasing the treatment effect and minimizing the side effects of liver cancer treatment.

The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and / or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and / or VEGF inhibitor in a subject. The method comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.

This application relates to the use of TLR agonists in combination with immune checkpoint inhibitors and VEGFR inhibitors in the preparation of drugs for treating tumors. Specifically, the TLR agonist involved in this application is a compound represented by formula (I) or its complex or a pharmaceutically acceptable salt thereof, and the immune checkpoint inhibitor is selected from PD‑1 inhibitors, PD‑L1 inhibitors or CTLA ‑4 inhibitor, the VEGFR inhibitor is apatinib or a pharmaceutically acceptable salt thereof.

The invention relates to a pharmaceutical composition of a VEGFR inhibitor and a preparation method thereof. Specifically, the present invention relates to a N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-picolinylmethyl group comprising a particle size D90 of less than about 10 μm A pharmaceutical composition of amides and a method for preparing the same, the pharmaceutical composition has improved individual variability compared with commercially available preparations.

The invention discloses a synthesis method of VEGFR inhibitor fruquintinib and its benzofuran intermediate. The synthesis method of VEGFR inhibitor fruquintinib in the invention comprises the following steps: S1: halogenation; S2: acyl S3: coupling; S4: ring closure; S5: hydrolysis; S6: amination; S7: substitution. The present invention has few synthetic steps, and the process is simple and easy to operate; no expensive and dangerous compounds are used in the synthetic process, and there is no safety risk; the method uses commercially available starting materials, and the cost is low, which ensures good reproducibility of the synthetic route and is A process suitable for large-scale industrial production.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).